Aldosterone Synthase Inhibition: Lowering Blood Pressure in Resistant Chronic Kidney Disease

Key Takeaway

In patients with chronic kidney disease, suppressing aldosterone directly at its enzymatic source—rather than blocking its receptor downstream—lowered systolic blood pressure by approximately 8 mmHg and reduced albuminuria by nearly one-third. While this blood pressure–lowering effect was remarkably consistent across clinical trials, uncertainties regarding potassium safety persist. Ultimately, definitive hard-outcome trials will determine whether this novel drug class secures a permanent role in cardiorenal therapeutics.

The Patient with Refractory Hypertension

Consider a 62-year-old man with stage 3 chronic kidney disease and type 2 diabetes. He is maintained on maximally tolerated doses of an angiotensin receptor blocker, a calcium channel blocker, and a thiazide diuretic, paired with strict dietary sodium restriction. Despite this regimen, his clinic systolic blood pressure stubbornly hovers around 148 mmHg, and his urinary albumin-to-creatinine ratio continues to climb. Clinical practice guidelines point to spironolactone as the logical next step; however, with his serum potassium already sitting at 5.1 mmol/L, his nephrologist rightfully hesitates^[2]. Every internist recognizes this clinical dilemma. In chronic kidney disease, hypertension is both exceedingly common and notoriously difficult to control. Paradoxically, the pharmacotherapies that best target the underlying hormonal drivers carry the very risk these compromised kidneys are least equipped to tolerate:…